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Background: Although several studies have found reduced plasma BDNF levels in patients 
with severe mental disorders, the sample sizes have been small and have exhibited variation 
and heterogeneity. Furthermore, long-term neurobiological changes following childhood 
trauma and clinical severity have been linked to a reduction in BDNF levels. Accordingly, we 
aim to clarify, using the largest sample size to date, the role of plasma BDNF in individuals 
with severe mental disorders in relation to the number of episodes, current remission status, 
and childhood trauma experiences. 
 
Methods: The study sample comprised 1446 individuals (schizophrenia: SZ [n=589]; bipolar 
disorder: BD [n=254]); and healthy control: HC [n=603]) all recruited from the same 
catchment area. A subsample (N=629) of this larger group had a history of childhood trauma, 
and some (N=195) participated in a one-year follow-up study. The level of BDNF in plasma 
was measured, and childhood trauma was assessed using the Childhood Trauma 
Questionnaire (CTQ). Diagnoses and episodes were obtained using the Structured Clinical 
Interview (SCID).  
 
Results: Patients with SZ or BD had lower levels of plasma BDNF than did the HC group 
(p=0.002, p=0.003, respectively). Within patients, reduced plasma BDNF levels were 
associated with more depressive episodes (p=0.04). Longer time in remission after depressive 
episodes was associated with higher plasma BDNF levels (p=0.02), and patients reporting 
childhood sexual abuse exhibited lower plasma BDNF levels (p=0.049) than patients without 
sexual abuse. 
 
Conclusion: Our study confirms that patients with a severe mental disorder exhibit reduced 
BDNF levels.  While the strongest reduction in BDNF was observed in patients reporting 
childhood sexual abuse, reduced BDNF levels were also associated with more depressive 
episodes. Accordingly, further studies are warranted to determine whether treatment that 








Schizophrenia spectrum disorder (SZ) and bipolar spectrum disorder (BD) affect 2 to 3% of 
the population and cause marked decrements in quality of life and life expectancy (Whiteford 
et al., 2013). The core characteristic of SZ is psychotic symptoms, whereas affective 
symptoms are at the core of BD. There is, however, an overlap in these symptoms, as 
described in the continuum hypotheses of the two disorders (Craddock and Owen, 2010). SZ 
and BD are highly heritable (Lichtenstein et al., 2009) and involve complex genetic and 
environmental interactions (Burmeister et al., 2008). Furthermore, childhood trauma, drug 
addiction and poor lifestyle are environmental factors associated with both of these disorders 
(Aas et al., 2016; Di Forti et al., 2015; Varese et al., 2012). Thus, because a substantial 
number of patients do not respond sufficiently to treatment (Mcgorry et al., 2014, Scott et al., 
2013), it is urgent to find relevant biomarkers and personalized treatment targets.  
 
Brain-derived neurotrophic factor (BDNF) is essential for the human brain. It is a protein 
produced by many cell types, including neurons and immune cells, and its levels are 
influenced by mental stress, exercise and diet (Firth et al., 2015, Solati et al., 2015). BDNF 
promotes neuronal growth and differentiation during brain development and increases 
synaptic plasticity and the maintenance of neurons in adult life (Nuernberg et al., 2016). 
Furthermore, BDNF crosses the blood-brain barrier (BBB) (Fernandes et al., 2015a), and its 
peripheral levels are highly correlated with its levels in the cerebrospinal fluid (r=0.8) 
(Fernandes et al., 2015a). Over the last decade, numerous studies have found low levels of 
peripheral BDNF in individuals with neurodegenerative and neuropsychiatric disorders 
(Nuernberg et al., 2016). Low levels of peripheral BDNF are observed in patients with both 
affective and non-affective severe mental disorders, including major depressive disorder 




To this end, mechanisms driving reductions in peripheral BDNF levels in individuals with 
these disorders are unclear. Later clinical illness course characterized by more episodes 
(Kauer-Sant'Anna et al., 2009, Fernandes et al., 2015a, Fernandes et al., 2015b, Nuernberg et 
al., 2016) and/or by being in a current mood or psychotic episode (Bus et al., 2015, Nuernberg 
et al., 2016) has been suggested to influence BDNF levels. BDNF has also been suggested as 
a marker of the stage of the illness (Fernandes et al., 2015a, Fernandes et al., 2015b, 
Nuernberg et al., 2016) whereby a lower BDNF level indicates the patient is in a later stage of 
the illness. Indeed, a recent meta-analysis of BD confirms that peripheral BDNF levels are 
reduced to the same extent within a manic or depressive episode but that they are not reduced 
not during a euthymic state (Fernandes et al., 2015b). Thus, the temporal relationship between 
peripheral plasma and serum BDNF levels and symptoms must be clarified. Bus et al., (2015) 
recently determined that patients with a treatment-resistant depression were more likely to 
have lower serum BDNF levels over a two-year period, whereas patients with higher serum 
BDNF levels were more likely to be in remission at follow-up. Hence, taking into 
consideration remission status when investigating peripheral BDNF levels and illness staging 
is warranted, especially given that these relationships are, at present, unclear in SZ and BD. 
 
In addition, interactions between high exposure to childhood trauma experiences and 
peripheral BDNF levels in plasma have been proposed (Aas et al., 2014b, Mondelli et al., 
2011). Childhood trauma is an influential risk factor for developing a wide range of mental 
illnesses, including psychotic disorders (Varese et al., 2012) and is also associated with a 
more severe disease course (Aas et al., 2016, Yung et al., 2015). BDNF protects the brain 
from the toxic effects of glucocorticoids (stress hormone) and supports neurogenesis (Taliaz 
et al., 2010). Glucocorticoids, on the other hand, suppress BDNF mRNA in the CA 3 region 
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of the hippocampus and reduce dendrite density accordingly (Bennett & Lagopoulos, 2014. 
)Although it has been previously concluded that experiences of severe stress, such as 
childhood traumas, reduce BDNF plasma levels (Mondelli et al., 2011; Aas et al., 2014b), it is 
possible that reduced BDNF plasma levels prior to childhood trauma worsen the adverse 
effects of childhood trauma experiences on brain development and promote more severe 
neurodevelopmental changes following trauma experiences. Thus, the influence of childhood 
trauma on BDNF within the psychosis continuum disorder and its association with illness 
must be further explored.  
 
Peripheral BDNF has been frequently studied in BD and SZ; however, the sample sizes in 
these studies have been small, i.e., less than 200, and recent meta-analyses may have been 
hampered by the variations in the BDNF measurement methodology and the heterogeneity 
among the populations included in the studies (Nuernberg et al., 2016). To address these 
issues, we investigated peripheral BDNF levels measured in plasma among a large group of 
individuals (N =1446) that consisted of patients with severe mental disorders, i.e., SZ or BD, 
and an HC group from the same catchment area. Specifically, we aimed to i) replicate reduced 
plasma BDNF levels in patients with psychosis continuum disorder compared to the HC 
group while correcting for childhood trauma experiences; ii) investigate whether plasma 
BDNF levels are associated with more affective and psychotic episodes as a marker of a more 
prolonged clinical staging during longitudinal testing; and iii) rule out that current 







MATERIALS AND METHODS 
Participants 
The participants were recruited consecutively from psychiatric units, both outpatient and 
inpatient, of 4 major hospitals in Oslo as part of the Thematically Organized Psychosis (TOP) 
study. All participants were recruited from the same catchment area that is composed of 
individuals of similar socio-economic status (SES) and ethnic backgrounds (88% 
Caucasians). A total of 1446 participants (individuals with schizophrenia [n=589], individuals 
with bipolar disorder [n=254]), and healthy individuals [n=603]) were recruited.  
A subset of individuals provided data regarding childhood trauma experiences, specifically, 
N=629 (SZ: N=263; BD: N=132; HC: N=234). In addition, data were collected from 195 
individuals provided one year after the initial study (N=195; SZ, N=51; BD, N=50; HC, 
N=94). Inclusion criteria for the clinical groups included age range between 18 and 65 years 
and a DSM diagnosis of schizophrenia spectrum disorder (SZ) or bipolar spectrum disorder 
(BD). Inclusion criteria for the healthy controls were included the following: live in the same 
district as the patients, beg between 18 and 65 years of age and have no diagnosis during their 
lifetime of a DSM1 disorder. Exclusion criteria for all groups included the following: organic 
psychosis, neurological disorder, unstable or uncontrolled medical conditions that interfere 
with brain function, and age outside the range of 18 to 65 years. The Regional Committee for 
Medical Research Ethics and the Norwegian Data Inspectorate approved the study. All 




Trained physicians, psychiatrists, and clinical psychologists performed clinical assessments. 
Diagnoses were based on the Structured Clinical Interview for DSM-IV Axis I disorders 
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(SCID-I), chapters A-E. All clinical personnel completed a training program in diagnostics 
and symptom rating that was based on the training program at UCLA (Los Angeles, 
California). The training program is based on the SCID 101 training videos and includes 
videos with reliability testing between SCID scorers (http://www.scid4.org/index.html). The 
diagnostic reliability was found to be satisfactory with an overall agreement regarding the 
DSM-IV diagnostic categories of 82% and an overall κ of 0.77 (95% CI: 0.60-0.94).  
 
Clinical characteristics  
Remission was measured in weeks. Remission of psychotic symptoms was defined as PANSS 
items below four for the following items: P1, P3, G9, P2, G5, N1, N4, and N6. Remission was 
based on Nancy Andreasen’s  six-month criteria (Andreasen, et al., 2015). Remission of 
affective episodes was based on the SCID definitions defined as symptoms during the last two 
months. The illness stage was measured by numbers of episodes and was calculated based on 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) verified episode criteria 
using the Structured Clinical Interview (SCID). According to these criteria, the following data 
were reported: N=513 (61%) had at least one depressive episode; N=665 (79%) had at least 
one psychotic episode; and N=201 (24%) had at least one manic episode. Within the SZ 
group, the distributions of depressive, psychotic and manic episodes (mean±SD) were 
2.77±10.18, 4.18±14.58, and 0.26±1.41, respectively. Within the BD group, the distributions 
of depressive, psychotic and manic episodes (mean±SD) were 6.23±9.98, 1.33±2.63, and 
2.07±6.78, respectively. Moreover, 45% of the patients had at least two types of episodes and 
15% had three types of episodes.  
 
Clinical illness stage modeling in psychiatry has adopted the numerical system that is used in 
medical staging models (Berk et al., 2017, McGorry et al., 2014, Scott et al., 2013). The 
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advantage of this model is that it explicitly considers the evolution of psychopathology during 
the development of a mental illness and emphasizes that the progression of the illness is by no 
means inevitable but rather that it can be altered by providing appropriate interventions that 
target individual modifiable risk and protective factors (McGorry et al., 2014). Stage 
progression is usually defined in four steps, namely, stage 0 is an asymptomatic stage or at-
risk or latency phase. Stage 1 is often called the prodromal phase and consists of stage 1A, 
which is a nonspecific distress period, and stage 1B, which is a subthreshold high-risk stage. 
Stage 2 is the first-illness episode stage. Stage 3 is characterized by single or multiple 
recurrences of illness episodes and consists of stage 3A, which is characterized by a 
recurrence/persistence of episodes; stage 3B, which is a first threshold relapse phase; and 
stage 3C, which is a stage noted by multiple relapses. Finally, stage 4 is a treatment resistance 
or chronic disease stage (Berk et al., 2017, McGorry et al., 2014). In the current study, the 
number of episodes was used as a measure of illness stage.  
 
BDNF measurement 
For the BDNF analysis, blood was drawn into EDTA-containing vials, and plasma was 
extracted and stored at -80 °C. BDNF levels were measured using enzyme immune-assay 
with antibodies from R&D systems (Stillwater, MN). Intra-and inter-assay coefficients of 
variance were less than 10%.  
 
Childhood trauma  
To measure childhood adverse events, we used the Childhood Trauma Questionnaire (CTQ), 
a retrospective questionnaire that assesses traumatic experiences in childhood. The CTQ has 
answers ranging from never true, rarely true, sometimes true, often true, to very true, and it 
yields a total score as well as five subscores, namely, physical, emotional and sexual abuse 
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and physical and emotional neglect (Bernstein et al., 1994). For this study, we focused on the 
most severe form and most studied subtype of childhood trauma, sexual abuse (Nemeroff 
2016). Thus, the main analysis was performed only for sexual abuse. In addition, a total 
trauma score was also calculated. Data were analyzed and divided into below or above the 
moderate to severe cutoff scores, as suggested by Bernstein et al., (1994). The reliability and 




Data were analyzed using Predictive Analytic software, SPSS, Version 22 (IBM Corp., USA), 
and continuous variables are presented as the mean±SD. For descriptive analyses (Tables 1), 
we used chi-square tests and univariate ANOVAs.  
 
Linear multiple regression analyses were performed to investigate the numbers of episodes 
and were divided into depressive, manic, and psychotic episodes. To test whether being in 
remission was associated with an increase in plasma BDNF levels (Berk et al., 2011), linear 
regression analyses were performed to determine whether the length (in weeks) of remission 
of affective (depressive or manic) or psychotic episodes was linked to an increase in plasma 
BDNF levels. Data were available for a subset of individuals for a year follow-up analysis 
(N=195; SZ: N=51; BD: N=50: healthy controls: N=94). Plasma BDNF levels at baseline, 
plasma BDNF levels at one-year follow-up and changes in plasma BDNF levels from baseline 
to the one-year follow-up, baseline minus follow-up, were compared to remission status at the 




Gender differences in BDNF signaling and functions are reported, and estrogens are found to 
have a potential positive regulatory effect on BDNF expression and signaling (Chan & Ye, 
2017). It has been suggested that gender differences exist in the relationship between 
childhood trauma and the clinical expression of patients with psychotic disorders and that 
women experience greater negative effects than men (Fisher et al., 2009; Garcia et al., 2016; 
Haug et al., 2014). Therefore, analyses investigating BDNF levels and reports of trauma, as 
well as analyses of the potential role of childhood trauma on BDNF levels, were performed 
separately on females and males before they were analyzed together as one group. In addition 
to gender, several other environmental factors have been linked to BDNF levels, including 
age, cigarette smoking and time of stored samples (Bus et al., 2011). Thus, all of these 
environmental factors were taken into account in the current study. To test staging based on 
the numbers of episodes and not on the length of the illness, age at first episode and current 
age were added into the multivariate model as independent variables. 
 
As current smoking status was available for the patient group but not for the healthy control 
group, smoking was corrected for only within the patient sample.  
 
To rule out medication as an influencing factor, current medications were included in the 
analyses and were accordingly divided into no current medication use, one type of 
antipsychotic medication use, two or more types of antipsychotic medication use, and 
antidepressant medication use (yes/no). The threshold for statistical significance was set at 









The socio-demographic and clinical characteristics of the total sample (N=1446), including 
the diagnostic subgroups (BD, SZ) and healthy controls are presented in Table 1. All 
participants were recruited from a catchment area in Norway. There were more males in the 
SZ group and more females in the BD group. There were more Caucasians in the healthy 
control group, 96%, compared to the patient group ≤71%. Patients with an SZ disorder had 
more psychotic episodes, while the BD group had more manic and depressive episodes. 
Controls had lower childhood trauma scores based on the CTQ than did both the SZ and BD 
groups (see Supplementary Material Table S1 for total CTQ scores and subtypes of trauma). 
Post hoc Bonferroni analyses revealed higher physical neglect scores among those with SZ 
compared to those with BD. Otherwise, there were no statistically significant differences in 
trauma scores between the two patient groups. 
 
-Please insert Table 1 around here- 
 
 
BDNF levels in relation to case-control status and number of episodes 
Plasma BDNF levels were higher among healthy controls than it was for patients with BD and 
SZ, p=0.003, p=0.002, respectively (see Figure 1). Post hoc differences were nonsignificant 
for patient comparisons, i.e., between patients with BD and patients with SZ. A within-patient 
analysis found there were no differences in BDNF levels between females and males 
(mean±SD: 5.82±3.76, 5.91±3.45, respectively, t=0.36 P=0.71). However, among healthy 
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individuals, a trend was observed for higher BDNF levels in females compared to males 
(mean±SD, 6.87± 3.63, 6.34±3.54, respectively, t=-1.84 P=0.067). 
 
The number of depressive episodes was associated with lower plasma BDNF levels in the 
population as a whole (ß=-0.07, t=-2.07, p=0.04). These findings were independent of time 
since sampling (in years), patient status, current age, gender, age at onset and daily smoking 
(yes/no) (Table 2). These findings remained significant when the state of current symptoms, 
i.e., in remission or not, was added into the model (ß=-0.08, t=-2.41, p=0.02). The 
relationship between plasma BDNF level and the number of psychotic or manic episodes was 
not significant (p˃0.1). Dividing into females and men, findings were similar for both  
females and men, however, the association was no longer statistical significant for either 
groups (data not shown). 
 
-Please insert Figure 1, Table 2 around here- 
 
 
BDNF levels and one-year remission status 
Longer time in remission from a depressive episode was associated with higher plasma BDNF 
levels (ß=0.19, t=2.32, p=0.02, Figure 2). No relationship was observed regarding the length 
of remission from a psychotic or manic episode and plasma BDNF levels (p˃0.1), and no 
associations were observed between plasma BDNF levels at baseline or plasma BDNF at 
follow-up and a classification of remitted at the one-year follow-up (p˃0.1, see 
Supplementary Material, Table S2) or between current antipsychotic or depressive medication 
and plasma BDNF levels at baseline or follow-up (p˃0.1). Twenty-five % of the patients were 
taking both antidepressants and antipsychotic medication at baseline.  
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-Please insert Figure 2 around here- 
 
BDNF levels and childhood trauma 
In the total sample, a dose-relationship was observed between more total childhood trauma 
experiences and lower BDNF levels (f=3.09, p=0.02; see Supplementary Material Figure S1). 
Moreover, childhood trauma was associated with reduced BDNF levels in both females and 
males, with the highest rho occurring in the female patients (see Table 3).  
Patients reported more frequent childhood sexual abuse experiences compared to the HCs, 
with 21% of the patients reporting sexual abuse experiences that reach levels of moderate to 
severe cut-off scores by Bernstein et al. (1994) compared to 3% among the HC group. With 
respect to the patients, childhood sexual abuse was associated with a reduction in plasma 
BDNF levels (f=3.08, p=0.049, see Supplementary Material Figure S2) and more psychotic 
and affective episodes (see Supplementary Material Figure S3 and Figure S4). Both females 
and males who reported childhood trauma experiences exhibited more episodes (p˂0.05). 
Even after correcting for childhood trauma experiences, patients still reported lower plasma 
BDNF levels than did the HC group (f=19.5, p˂0.001).  
 
 











In this large population of patients with bipolar disorder (BD) or schizophrenia spectrum 
disorder (SZ), peripheral plasma BDNF levels were decreased compared to the healthy 
control (HC) group. Low peripheral plasma BDNF levels were associated with more 
depressive episodes, thus indicating a more severe illness (Mcgorry et al., 2014). Our data 
from this large study support reduced BDNF levels as a potential biomarker for clinical 
staging in patients with severe mental disorders, as suggested by previous smaller studies 
(Berk et al., 2017, Fernandes et al., 2015a, Fernandes et al., 2015b, Nuernberg et al., 2016).  
Furthermore, we observed that more episodes (depressive, but not psychotic, or manic) were 
associated with reduced plasma BDNF levels even after correcting for potential confounders. 
Previous research indicates that more episodes are linked to treatment resistance, cognitive 
impairments (Aas et al., 2014, Berk et al., 2017, Ortiz et al., 2017) and reduced hippocampal 
volume, all of which are part of the staging model (Berk et al., 2017, Mcgorry et al., 2014). 
Our study provides new knowledge on the number of episodes and biological mechanisms, 
including the reduction in plasma BDNF levels.   
 
Our data also indicate that patients currently in remission from a depressive episode 
demonstrate higher plasma BDNF levels, suggesting that reduced plasma BDNF levels are 
associated with ongoing disease. Our findings are consistent with a large study of individuals 
with MDD conducted by Bus et al., (2015). Their study concluded that patients who remained 
in a depressive episode without responding to treatment over a two-year period exhibited 
lower peripheral BDNF levels. In our subsample of data collected one year after the initial 
study, no significant relationship was observed between peripheral plasma BDNF levels and 
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remission. However, it is noted that for our one-year-follow-up study, the sample was rather 
small, specifically, 101 patients and 94 HCs.  
 
 
Our study determined that the patients exhibited reduced plasma BDNF levels compared to 
the control group even after correcting for childhood trauma experiences. As a history of 
childhood trauma was negatively correlated with BDNF levels, our study indicated that 
childhood trauma resulted in a reduction in BDNF levels combined with a further non-trauma 
BDNF reduction in the patient group. The research indicates that approximately 10% or more 
of the general population reports a history of childhood trauma (Pruessner et al., 2017, Aas et 
al., 2016). It could be hypothesized that low BDNF levels reduce resilience to childhood 
trauma during brain development, thus linking trauma to psychopathology. As glucocorticoid 
also reduces BDNF mRNA levels in the hippocampus, a brain area important for cognition 
(Bennett & Lagopoulos, 2014), patients with low plasma BDNF levels who have a history of 
childhood trauma, i.e., a history of severe stressors, may be more inclined to exhibit a more 
progressive illness as characterized by more episodes. This hypothesis must be further 
clarified in future studies. As recently suggested, treatment aimed to increase BDNF levels 
may have a positive effect among patients with BD and SZ (Berk et al., 2017, Fernandes et 
al., 2015a, Fernandes et al., 2015b, Nuernberg et al., 2016). For example, 90 minutes of 
weekly physical exercise may increase BDNF levels and reduce depressive symptoms (Firth 
et al., 2015). Another potential treatment to increase BDNF levels is food supplements with 
zinc. Interestingly, zinc increased serum BDNF levels and decreased depressive symptoms in 
overweight and obese subjects in a double-blind, randomized, placebo-controlled trial (Solati, 




It has been suggested that females exhibit higher BDNF levels than males (Chan & Ye, 2017). 
In our study, however, while a trend was observed for higher plasma BDNF levels in healthy 
females, with respect to the patients, no differences between females and males were 
observed for plasma BDNF levels. We also found that irrespective of gender, a history of 
childhood trauma was significantly associated with a reduction in plasma BDNF levels and 
more clinical episodes.  
The strength of the current study is the large N and the homogeneity of the sample. That is, 
the participants were all recruited from the same catchment area, which was composed of 
individuals with similar socioeconomic backgrounds within a welfare society. The current 
study has some limitations. The relevance of a staging model for schizophrenia has been 
questioned (Bora et al., 2017). Furthermore, investigating numbers of episodes as a marker of 
staging and clinical severity may be biased by disease characteristics. Some individuals may 
have a more severe and deteriorating presentation and course from onset, while others may 
have an episodic illness with full inter-episode recovery. Additionally, a linear progression of 
a serial of phases may not apply to the course of a disease in all patients. It is also unclear 
whether treatment resistance leads to more episodes or whether more episodes lead to 
treatment resistance, as suggested in the stage modeling of severe mental disorders (Mcgorry 
et al., 2014, Scott et al., 2013). Reduced peripheral BDNF levels were also associated more 
with depressive than with psychotic or manic episodes, indicating that BDNF levels may be 
related to affective rather than non-affective episodes. Moreover, a history of childhood 
sexual abuse was collected retrospectively by asking adults about experiences in childhood. 
As retrospective interviews correlate with longitudinal case notes about trauma history 




To conclude, our study demonstrates reduced BDNF levels in patients with severe mental 
disorders. Reduced BDNF was found across patients diagnosed with SZ and BD, with the 
most substantial reduction in patients reporting childhood sexual abuse. Our findings support 
an association between reduced peripheral plasma BDNF levels and more affective episodes, 
i.e., a putative marker of illness severity. Future studies should include not only numbers of 
episodes but also other factors suggested for clinical staging, including cognitive function, 
and structural MRI measures. Reduced plasma BDNF levels could be one biomarker of a 
more severe clinical course, thus suggesting that treatments designed to increase levels of 





Figure 1: Patients with a psychosis continuum disorder have reduced plasma BDNF levels 
compared to healthy individuals. 
 
Figure 2: Longer time in remission of an affective episode is associated with higher plasma 
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Sex, M  n (%) 99 (39.8) 349 (59.9) 317 (51.8) X2=29.8 <0.001 
Age, years mean±SD 33.5±11.7 30.0±9.8 32.8±9.6 F=16.1 <0.001 
 Caucasians n (%) 226 (89.0) 463 (78.6) 588 (96.1) X2=109.9 <0.001 
Psychotic episodes, mean±SD 1.3±2.5 2.4±3.7  F=10.9 0.001 
Manic episodes, mean±SD 1.7±2.8 0.3±1.4  F=91.8 <0.001 
Depressive episodes, mean±SD 5.8±8.0 2.0±5.9  F=54.5 <0.001 
BDNF plasma, mean±SD* 5.7±3.3 6.0±3.8 6.6±3.6 F=7.9 <0.001 
Daily smoking, yes (%) 139 (54.7) 316 (54.4)  X2<0.01 0.93 
3 missing data on ethnicity. Ethnicity,” other” consists of 32 Africans, 9 Hispanics, 2 Same, 64 Asians, 29 Arabic, mixed or other=30.  Log 











Table 2: Number of episodes and BDNF levels 
  Variable                       se             ß             t                   p 
 Psychotic 
episodes* 
0.008 0.06 1.40 0.16 
 Depressive 
episodes* 
0.003 -0.11 -2.07 0.04 
Manic episodes* 0.01 0.09 1.04 0.30 











































































ANOVA, f=7.95, p<0.001. BD, N=254; SZ, N=589,  HC, N=603. Controls ˃ SZ, BD. No 
statistical significant differences in BDNF levels within the patients group.  BD=bipolar 
























                                                                 
 
 










Table S1:  Childhood trauma stratified into groups  
 SZ BD HC Statistics Posthoc 
CTQ total score, 
mean±SD 





























CTQ= Childhood Trauma Questionnaire. SZ= schizophrenia, BD= Bipolar Disorder; HC= 




Table S2: 1 year follow-up and BDNF levels (N=91) 
 
 BDNF levels  
1 year follow-up 
BDNF change 
from baseline to 
1 year follow-up 
 
Remission baseline n.s. n.s. 
Remission 1 year follow-up,  n.s. n.s. 
GAF, baseline n.s. n.s. 
GAF, 1 year follow-up n.s. n.s. 
PANSS, baseline n.s. n.s. 
PANSS, year follow-up n.s. n.s. 
Analyses adjusted for sex, age, cigarette smoking and time of stored samples.GAF=Global 
Assessment of Functioning Scale, PANSS=Positive and Negative Syndrome scale. BDNF= 
























F=3.09, P=0.02. 0=no trauma, N=386, 1=one type of childhood trauma, N=101; 2=two types 














Figure S2: Patients reporting sexual abuse had lower BDNF levels than patients who did not 




F=3.08, p=0.049.  “No childhood sexual abuse”, N=337; 1=”Childhood sexual abuse”, N=88. 
Childhood sexual abuse was defined as having moderate to severe score on the childhood 

























Figure S3: Patients reporting sexual abuse had more depressive episodes 
 
 
F=6.69, p=0.01. “No childhood sexual abuse”, N=326; “childhood sexual abuse”, N=82. 
Childhood sexual abuse was defined as having moderate to severe score on the childhood 


























Figure S4: Patients with childhood sexual abuse reported more psychotic episodes 
 
 
F=5.41, p=0.02. “No childhood sexual abuse”, N=318; “childhood sexual abuse”, N=81. 
Childhood sexual abuse was defined as having moderate to severe score on the childhood 
sexual abuse domain from the CTQ (Bernstein et al., 1994).  
 
 
 
 
